Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDXH
MDXH logo

MDXH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy MDxHealth SA (MDXH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.240
1 Day change
-2.61%
52 Week Range
5.330
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

MDxHealth SA (MDXH) is not a strong buy at the moment for a beginner investor with a long-term horizon. The technical indicators show a bearish trend, and there are no positive catalysts or trading signals to suggest immediate upside potential. Given the oversold RSI, the stock may stabilize or rebound slightly in the short term, but the lack of financial data, news, and trading trends makes it unsuitable for immediate investment.

Technical Analysis

The stock shows a bearish trend with MACD negatively expanding (-0.054), RSI indicating oversold conditions (12.408), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 2.801 and 2.599, with resistance at 3.127 and 3.454.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends to act as positive catalysts.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of significant hedge fund or insider activity, and no recent news or financial performance data.

Financial Performance

No financial performance data available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for MDXH.

Wall Street analysts forecast MDXH stock price to rise
5 Analyst Rating
Wall Street analysts forecast MDXH stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.240
sliders
Low
7
Averages
7.67
High
9
Current: 2.240
sliders
Low
7
Averages
7.67
High
9
BTIG
Buy
maintain
$6 -> $7
AI Analysis
2025-11-13
Reason
BTIG
Price Target
$6 -> $7
AI Analysis
2025-11-13
maintain
Buy
Reason
BTIG raised the firm's price target on MDxHealth to $7 from $6 and keeps a Buy rating on the shares. The company drove a big uplift in its liquid-based test volumes in Q3 in part due to strength from its Resolve test and new contribution from its recently acquired ExoDx test, which the company recently acquired from Bio-Techne, the analyst tells investors in a research note. MDxHealth's reported Q3 was also highlighted by robust volume growth, the firm added.
TD Cowen
Buy
upgrade
$5 -> $7
2025-11-13
Reason
TD Cowen
Price Target
$5 -> $7
2025-11-13
upgrade
Buy
Reason
TD Cowen raised the firm's price target on MDxHealth to $7 from $5 and keeps a Buy rating on the shares. The firm said 3Q sales were just shy of consensus with margins/EBITDA better. 2026 should see accelerating sales growth as ExoDx integration takes full effect, which combined with OpEx control will enable expanding positive EBITDA, supporting a favorable view on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDXH
Unlock Now

People Also Watch